Business Wire

Altasciences’ Commitment to Supporting Pharma and Biotech With Comprehensive Bioanalytical Services

13.11.2024 18:00:00 CET | Business Wire | Press release

Share

Altasciences, a trusted drug development research partner for over 30 years, continues its commitment to providing world-class bioanalytical services. This core business supports both preclinical and clinical studies conducted at Altasciences’ facilities, while also offering an extensive standalone solution to meet the diverse needs of clients. By delivering high-quality, flexible bioanalytical services, Altasciences remains dedicated to advancing drug development and empowering clients across every phase of research.

For three decades now, Altasciences has taken pride in evolving their solutions to meet the needs of pharmaceutical and biotechnology companies of all sizes, including the expansion of their labs in Seattle, WA, Columbia, MO, and Laval, Québec. Their three state-of-the-art bioanalytical laboratories feature mirrored operations and uniform protocols to maintain consistency and quality across client projects, ensuring reliable, high-quality data regardless of location. This high level of harmonization enables the seamless transfer and sharing of methods across its multiple laboratory sites, allowing the analysis of hundreds of thousands of samples efficiently.

“Our extensive bioanalytical offerings are designed to support both standalone projects and Altasciences' integrated drug development solutions. Whether for preclinical or clinical studies, we provide tailored solutions to meet specific research needs. At Altasciences, we’re committed to facilitating every phase of the scientific journey with precision and care,” said Dr. Lynne Le Sauteur, Vice President of Laboratory Sciences at Altasciences.

Altasciences’ bioanalytical services are built around a comprehensive suite of capabilities tailored for both small and large molecules. Core offerings include drug quantification, metabolite and biomarker analysis, and immunogenicity testing, to support and advance a molecule from discovery to market.

Altasciences’ bioanalytical approach focuses on three core pillars: understanding and anticipating client needs as scientists, creating innovative solutions, and fostering collaboration through transparent communication. This client-centered approach has helped Altasciences build lasting partnerships, assisting clients in meeting complex regulatory standards while maintaining scientific rigor.

To promote Altasciences’ bioanalytical services from discovery to Phase IV, they recently launched Unveiling the Invisible, a video campaign that showcases how their bioanalytical solutions provide critical insights that unveil the invisible and drive the creation of innovative therapies.

View the fascinating video series here.

About Altasciences
Altasciences is an integrated drug development solution company offering pharmaceutical and biotechnology companies a proven, flexible approach to preclinical and clinical pharmacology studies, including formulation, manufacturing, and analytical services. For over 25 years, Altasciences has been partnering with sponsors to help support educated, faster, and more complete early drug development decisions. Altasciences’ integrated, full-service solutions include preclinical safety testing, clinical pharmacology and proof of concept, bioanalysis, program management, medical writing, biostatistics, clinical monitoring, and data management, all customizable to specific sponsor requirements. Altasciences helps sponsors get better drugs to the people who need them, faster. To learn more about Altasciences, visit Altasciences.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20241113252394/en/

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Reply and IEO Launch Collaboration to Co-Develop and Train Domain-Specific Large Language Models for Oncology4.6.2026 10:10:00 CEST | Press release

Reply [EXM, STAR: REY] and the European Institute of Oncology (IEO) have launched a collaboration focused on the co-development and training of domain-specific Large Language Models for oncology. The initiative brings together Reply’s expertise in building frontier generative models grounded in enterprise knowledge with the IEO’s clinical expertise and data assets to develop models tailored to highly complex oncology settings. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260604488955/en/ Reply and the European Institute of Oncology (IEO) have launched a collaboration focused on the co-development and training of domain-specific Large Language Models for oncology. As a first step, the IEO’s clinical teams and Information Systems department are working with a multidisciplinary Reply team with deep expertise in healthcare and LLM specialisation to define and prioritise the use cases that will guide development, while also map

UK AI Minister Kanishka Narayan Joins The AI Summit London as 10th Anniversary Agenda Expands Across Enterprise AI, Innovation and Policy4.6.2026 10:00:00 CEST | Press release

London Tech Week's flagship AI event will feature 300 speakers, live AI demonstrations, startup pitch competitions, executive training and the National AI Awards The AI Summit London today revealed the full agenda for its highly anticipated 10th anniversary edition, delivering its most expansive and future-focused programme to date. Taking place 10–11 June at Tobacco Dock as the headline AI event of London Tech Week 2026, the Summit expects more than 5,000 attendees, 300 speakers, 100+ sponsors and exhibitors, and a special executive presentation from Kanishka Narayan, Minister for AI and Online Safety, Department for Science, Innovation and Technology, across two days dedicated to the commercial realities and transformative potential of artificial intelligence. The 10th anniversary has been designed to move the conversation beyond experimentation and into enterprise-wide execution. New in 2026, the programme introduces The AI Impact Arena, delivering focused briefings and live demos,

Corona Launches 2026 Beach 100 Guide, Invites The World To Explore The Outdoors This Summer4.6.2026 10:00:00 CEST | Press release

Ahead of World Oceans Day, the global beach authority returns with a list of new locations, over 300,000 Tripadvisor experiences, and dedicated beach grants as part of its “This is Living” platform Corona, the world’s most valuable beer brand1, today announced the return of its annual global beach guide, the 2026 Corona Beach 100, ahead of World Oceans Day on June 8. The highly anticipated second edition spotlights 100 breathtaking and varied ocean-front destinations around the world while celebrating the natural ecosystems and local communities that help bring them to life. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260604412899/en/ 2026 Corona Beach 100 - Legzira Beach, Morocco Connected to Corona’s “This Is Living” platform, which invites consumers to step outside and live life to the fullest this summer, the 2026 guide features 27 new beaches, hundreds of localized Tripadvisor travel experiences inspired by the world

Lantern Expands Its Platform for Solving the Data Trust Problem with Strategic Acquisition and Key Executive Hires4.6.2026 10:00:00 CEST | Press release

Lantern Acquires Freyda to Create the First End-to-End Data Assurance Platform for Private Markets Lantern Limited (“Lantern”), the data assurance platform for private markets, announced today a strategic acquisition, expanded platform capabilities, and key leadership additions to address one of private markets biggest operational challenges: transforming fragmented, disconnected data across multiple sources into trusted, actionable intelligence. Private markets run on data, yet much of that data remains siloed, trapped in PDFs, and processed through highly manual workflows across both fund managers and investors. While GPs have increasingly modernized how they manage and report fund information internally, LPs still spend billions of dollars each year manually extracting, normalizing, and reconciling data from capital notices, quarterly statements, and other fund documents. With the acquisition of Freyda Limited (“Freyda”), one of the leading AI document intelligence platforms for ins

KAYTUS Launches MotusAI Enterprise Token Management Platform4.6.2026 09:02:00 CEST | Press release

KAYTUS, a leading provider of AI infrastructure and liquid cooling solutions, today announced the launch of enterprise-grade token management capabilities within MotusAI, enabling organizations to rapidly build, deploy, and operate secure on-premises AI token platform. This pioneering infrastructure enhancement transforms traditional GPU hardware into a unified, governable, and highly efficient internal token service ecosystem. By enabling rapid private deployment, MotusAI provides enterprises with a cost-competitive foundation for accelerating the scale-up of enterprise-grade AI agents while ensuring strong data privacy. Why Enterprises Must Build a Private Token Management Platform Now? As enterprise AI evolves from isolated model-based tools to interconnected AI agent systems that enable deep workflow automation, tokens are emerging as the fundamental “computing currency” of the modern organization. While standard LLM queries typically involve predictable, one-off inference requests

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye